Drugs / IMC-P115C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07156136 | Nov 2024 → Sep 2027 expected | cancer | Immunocore Ltd | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-12-23 | Immunocore Ltd | Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME immunocore.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-P115C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07156136 ↗ |
| Modality | Protein / enzyme biologic | “half-life extended (HLE) ImmTAC” NCT07156136 ↗ |
| Route | Intravenous | “IV infusion” NCT07156136 ↗ |
| Target | PRAME | “targeting PRAME” NCT07156136 ↗ |